CSIMarket
 

Verrica Pharmaceuticals Inc   (VRCA)
Other Ticker:  
 

Verrica Pharmaceuticals Inc 's

Competitiveness


 

VRCA Sales vs. its Competitors Q3 2023







Revenue Growth Comparisons




Net Income Comparison




<<  VRCA Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Verrica Pharmaceuticals Inc Contracts

Verrica Pharmaceuticals Secures Permanent J-Code for First FDA-Approved Molluscum Contagiosum Treatment

Verrica Pharmaceuticals, a leading dermatology therapeutics company, has recently received a significant milestone in its quest to provide medical interventions for skin diseases. The Centers for Medicare and Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica's groundbreaking medication, YCANTH. This marks a crucial step forward in treating molluscum contagiosum, a common skin condition affecting millions worldwide.Promoting Access to Innovative TreatmentMolluscum contagiosum is a viral skin infection characterized by small, raised, and painless lesions on the skin. It most commonly affects children, but can also impact adults, particularly those with weakened immune systems. Until now...





Who are Verrica Pharmaceuticals Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com